Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This study is a phase II, multicenter, randomized, blind, placebo-controlled to evaluate the
safety, tolerance, efficacy of ASC22 injection in combination with anti-retroviral therapy to
treat subjects living with human immunodeficiency virus type 1.